Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom Sells 10,000 Shares

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CFO Alexandra Balcom sold 10,000 shares of the stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $89.19, for a total transaction of $891,900.00. Following the completion of the sale, the chief financial officer now owns 33,300 shares in the company, valued at approximately $2,970,027. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Alexandra Balcom also recently made the following trade(s):

• On Monday, September 30th, Alexandra Balcom sold 10,000 shares of Nuvalent stock. The stock was sold at an average price of $101.06, for a total transaction of $1,010,600.00.
• On Friday, August 30th, Alexandra Balcom sold 10,000 shares of Nuvalent stock. The stock was sold at an average price of $84.23, for a total transaction of $842,300.00.

Nuvalent Stock Performance

Nuvalent stock traded up $0.31 during mid-day trading on Monday, reaching $89.53. The company's stock had a trading volume of 486,592 shares, compared to its average volume of 441,376. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of -32.21 and a beta of 1.33. Nuvalent, Inc. has a 12 month low of $55.25 and a 12 month high of $113.51. The business's 50 day simple moving average is $96.00 and its 200 day simple moving average is $81.67.

Nuvalent (NASDAQ:NUVL - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). During the same quarter in the prior year, the company earned ($0.51) EPS. As a group, sell-side analysts expect that Nuvalent, Inc. will post -3.52 EPS for the current year.

Institutional Trading of Nuvalent

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC acquired a new stake in Nuvalent in the 3rd quarter worth about $490,000. State of New Jersey Common Pension Fund D acquired a new stake in Nuvalent in the 3rd quarter worth about $2,412,000. AlphaCentric Advisors LLC acquired a new stake in Nuvalent in the 3rd quarter worth about $716,000. Harbor Capital Advisors Inc. raised its stake in Nuvalent by 29.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 21,516 shares of the company's stock worth $2,201,000 after purchasing an additional 4,957 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Nuvalent by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,417 shares of the company's stock worth $1,168,000 after purchasing an additional 4,472 shares in the last quarter. Institutional investors own 97.26% of the company's stock.

Wall Street Analyst Weigh In

NUVL has been the topic of a number of research analyst reports. UBS Group initiated coverage on shares of Nuvalent in a report on Thursday, October 24th. They set a "neutral" rating and a $100.00 price objective on the stock. Stifel Nicolaus raised their price objective on shares of Nuvalent from $115.00 to $135.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Guggenheim raised their price objective on shares of Nuvalent from $99.00 to $105.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Lifesci Capital upgraded shares of Nuvalent to a "strong-buy" rating in a report on Monday, July 29th. Finally, BMO Capital Markets raised their price objective on shares of Nuvalent from $102.00 to $132.00 and gave the stock an "outperform" rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Nuvalent currently has an average rating of "Moderate Buy" and an average price target of $112.40.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.